Merck & Co. has delivered a one-two legal punch against Halozyme Therapeutics, clearing major commercialization hurdles for ...
But regulatory approval is, in many ways, just the beginning of a complex journey to market for these companies, should their ...
The FDA's complete response letter for Summit Therapeutics and Akeso's ivonescimab reveals more grievances than just an ...
Though the quest to locate the regulator’s next commissioner hit a snag this week, the FDA has nevertheless been bringing ...
After Sanofi leadership telegraphed an upsized appetite for business development last month, signals have emerged that the ...
Novo will trim 215 jobs reporting to its New Jersey headquarters starting in February as part of a "redesign" of its U.S.
Facing an extended drought of options, patients with type 3 Gaucher disease (GD3) are getting a new treatment that's also the ...
Speaking on a press call ahead of Thursday’s investor presentation, CEO Vas Narasimhan attributed the lower growth target to ...
The FDA has slammed Johnson & Johnson over misleading claims about its bladder cancer drug Inlexzo, accusing the pharma ...
After delaying the phase 3 readout of its Alzheimer’s psychosis program for Cobenfy earlier this year, Bristol Myers Squibb ...
Lotte Biologics, a South Korea-headquartered CDMO established in 2022, has inked a large manufacturing deal with an unnamed ...
Underscoring how crowded the U.S. market for generalized myasthenia gravis (gMG) has become, the FDA on Wednesday approved ...